Jöhrens Korinna, Grassow Maja, Baretton Gustavo, Sperling Florian
Institut für Pathologie, Universitätsklinikum Carl Gustav Carus Dresden, Fetscherstr. 74, 01307, Dresden, Deutschland.
Qualitätssicherungs-Initiative Pathologie QuIP GmbH, Berlin, Deutschland.
Pathologie (Heidelb). 2022 Sep;43(5):346-350. doi: 10.1007/s00292-022-01102-3. Epub 2022 Aug 10.
The precise performance of immunohistochemical and molecular examinations of diagnostic and predictive markers is essential for the further therapy of patients. Due to the increasing number of biomarkers and their detection at the immunohistochemical and molecular level in patient tissue, the pathology has a direct influence on the therapy of patients, which increases the value of external quality assurance (EQA). In pathology, various forms are available for this purpose, such as proficiency tests. The standards of both the certification and accreditation procedures of pathology require regular participation in EQA and a statement on the EQA policy of the institutes. The quality of an EQA depends on the scientific concept, the adequate selection of material, the evaluation concept, and the communication of results.
对诊断和预测标志物进行准确的免疫组织化学和分子检测，对患者的后续治疗至关重要。由于生物标志物数量不断增加，且在患者组织的免疫组织化学和分子水平上进行检测，病理学对患者治疗有直接影响，这增加了外部质量保证（EQA）的价值。在病理学中，为此有多种形式可供使用，如能力验证试验。病理学的认证和认可程序标准都要求定期参与EQA，并就各机构的EQA政策发表声明。EQA的质量取决于科学概念、材料的适当选择、评估概念以及结果的传达。
